Mobile

A double blind, randomised, dose finding, repeat dose, phase II, multicentre study of Alpharadin TM for the treatment of patients with hormone refractory prostate cancer and skeletal metastases

Mise à jour : Il y a 4 ans
Référence : EUCTR2005-003680-22

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To compare the proportion of patients with PSA response (PSA decrease of 50% from baseline, confirmed three weeks later) of three different repeat dose regimens of Alpharadin in patients with hormone refractory prostate cancer and skeletal metastases.

Critère d'inclusion

  • Hormone refractory prostate cancer and skeletal metastases

Liens